tiprankstipranks
Advertisement
Advertisement
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
PremiumClass ActionAldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
2M ago
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
Premium
Company Announcements
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
2M ago
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
Premium
Ratings
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
3M ago
FDA Issues Second Complete Response Letter for Reproxalap
PremiumCompany AnnouncementsFDA Issues Second Complete Response Letter for Reproxalap
3M ago
Aldeyra options imply 10.9% move in share price post-earnings
Premium
The Fly
Aldeyra options imply 10.9% move in share price post-earnings
3M ago
Aldeyra Therapeutics Announces Chief Development Officer Resignation
Premium
Company Announcements
Aldeyra Therapeutics Announces Chief Development Officer Resignation
5M ago
Aldeyra Therapeutics Faces FDA PDUFA Date Extension
PremiumCompany AnnouncementsAldeyra Therapeutics Faces FDA PDUFA Date Extension
6M ago
Aldeyra announces PDUFA extension for Reproxalap
Premium
The Fly
Aldeyra announces PDUFA extension for Reproxalap
6M ago
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
Premium
Company Announcements
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100